Jefferies Group LLC assumed coverage on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a report issued on Thursday. The brokerage issued a positive rating on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Gilead Sciences’ Q3 2017 earnings at $1.86 EPS, Q4 2017 earnings at $1.66 EPS, FY2017 earnings at $8.21 EPS, Q1 2018 earnings at $1.58 EPS, Q2 2018 earnings at $1.54 EPS, Q3 2018 earnings at $1.49 EPS, Q4 2018 earnings at $1.52 EPS and FY2018 earnings at $6.15 EPS.
A number of other equities analysts have also weighed in on GILD. William Blair restated an outperform rating on shares of Gilead Sciences in a report on Friday, June 16th. Morgan Stanley restated an equal weight rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Royal Bank Of Canada began coverage on shares of Gilead Sciences in a report on Thursday, September 14th. They issued an outperform rating and a $94.00 price objective for the company. Robert W. Baird restated an outperform rating and issued a $87.00 price objective on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, Berenberg Bank set a $86.00 price objective on shares of Gilead Sciences and gave the stock a buy rating in a report on Tuesday, August 29th. Twelve analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of Buy and a consensus target price of $85.66.
Shares of Gilead Sciences (NASDAQ GILD) traded down 1.64% during mid-day trading on Thursday, hitting $82.14. The company had a trading volume of 5,797,031 shares. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27. The firm has a 50-day moving average price of $80.97 and a 200-day moving average price of $71.66. The firm has a market capitalization of $107.27 billion, a PE ratio of 8.92 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period in the previous year, the firm posted $3.08 EPS. The business’s revenue for the quarter was down 8.2% compared to the same quarter last year. Equities analysts forecast that Gilead Sciences will post $8.75 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This report was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2017/10/08/gilead-sciences-inc-gild-research-coverage-started-at-jefferies-group-llc.html.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.53%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the transaction, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the transaction, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The disclosure for this sale can be found here. Insiders sold a total of 486,819 shares of company stock valued at $39,298,919 in the last ninety days. 1.30% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Seizert Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 4.6% during the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after purchasing an additional 27,547 shares during the last quarter. Linscomb & Williams Inc. boosted its holdings in shares of Gilead Sciences by 3.0% during the 1st quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock valued at $358,000 after purchasing an additional 154 shares during the last quarter. Investment Centers of America Inc. boosted its holdings in shares of Gilead Sciences by 7.2% during the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after purchasing an additional 1,958 shares during the last quarter. HealthInvest Partners AB boosted its holdings in shares of Gilead Sciences by 3.5% during the 1st quarter. HealthInvest Partners AB now owns 117,000 shares of the biopharmaceutical company’s stock valued at $7,947,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Capital Asset Advisory Services LLC bought a new position in shares of Gilead Sciences during the 2nd quarter valued at about $875,000. 73.99% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.